Necrotizing vasculitis--a 2009 update.
Necrotizing vasculitis continues to be a condition where difficult diagnostic and treatment decisions need to be made, with only a few well-done studies as clinical reference and support. New data suggest that both methotrexate and azathioprine may be effective agents for maintaining remission in antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis after remission is achieved with cyclophosphamide-based therapies. In addition, Behcet's syndrome appears to be more common than previously assumed and is likely more common than a combination of ANCA-associated vasculitis (AAV) syndromes.
Sharaf
Pamela H
PH
Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, New York, USA.
Yazici
Yusuf
Y
D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy; D001379:Azathioprine / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy; D015267:Churg-Strauss Syndrome / Q000188:drug therapy; D019317:Evidence-Based Medicine; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D055953:Microscopic Polyangiitis / Q000188:drug therapy; D009336:Necrosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014657:Vasculitis / Q000175:diagnosis / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D001379:Azathioprine; D008727:Methotrexate